China approved a recombinant protein subunit vaccine against COVID-19 for emergency use. The vaccine was developed by the CAS Institute of Microbiology and Anhui Zhifei Longcom and is manufactured using CHO cells. It is the fourth vaccine approved in China for emergency use against COVID-19. It is currently in phase III clinical trials in Uzbekistan, Pakistan, Ecuador and Indonesia, with plans to inoculate a total of 29,000 volunteers.
China Daily, March 16, 2021